(DHI) DR Horton - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US23331A1097
Single-Family Homes, Townhomes, Mortgages, Title Services, Lot Development
Dividends
| Dividend Yield | 1.04% |
| Yield on Cost 5y | 2.35% |
| Yield CAGR 5y | 15.72% |
| Payout Consistency | 83.1% |
| Payout Ratio | 14.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 34.7% |
| Value at Risk 5%th | 53.2% |
| Relative Tail Risk | -6.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -13.88 |
| CAGR/Max DD | 0.59 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.393 |
| Beta | 0.544 |
| Beta Downside | 0.140 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.28% |
| Mean DD | 13.48% |
| Median DD | 10.25% |
Description: DHI DR Horton December 03, 2025
D.R. Horton (NYSE:DHI) is the largest homebuilder in the United States, operating across 125 markets in 36 states and offering single-family detached homes as well as attached townhomes, duplexes, and triplexes. The company also provides ancillary services such as mortgage financing, title insurance, and closing services, and it has expanded into residential lot development, multifamily rentals, and non-residential real estate assets.
Key recent metrics: FY 2023 revenue reached approximately $12.5 billion with a net income of $1.7 billion, while the company’s backlog-homes under contract-stood near $22 billion, indicating strong demand. Average selling price (ASP) rose to about $350 k, reflecting a shift toward higher-priced “move-up” buyers. The homebuilding sector remains sensitive to mortgage-rate movements and labor-cost pressures, but D.H.I.’s diversified geographic footprint helps mitigate regional economic cycles.
For a deeper, data-driven look at D.R. Hortons valuation and risk profile, consider exploring the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (3.59b TTM) > 0 and > 6% of Revenue (6% = 2.06b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 3.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 93.95% (prev 88.88%; Δ 5.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 3.42b <= Net Income 3.59b (YES >=105%, WARN >=100%) |
| Net Debt (3.05b) to EBITDA (4.84b) ratio: 0.63 <= 3.0 (WARN <= 3.5) |
| Current Ratio 17.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (297.4m) change vs 12m ago -9.14% (target <= -2.0% for YES) |
| Gross Margin 23.70% (prev 25.91%; Δ -2.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.70% (prev 101.9%; Δ -6.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 156.4 (EBITDA TTM 4.84b / Interest Expense TTM 30.3m) >= 6 (WARN >= 3) |
Altman Z'' 12.73
| (A) 0.91 = (Total Current Assets 34.14b - Total Current Liabilities 1.96b) / Total Assets 35.47b |
| (B) 0.88 = Retained Earnings (Balance) 31.04b / Total Assets 35.47b |
| warn (B) unusual magnitude: 0.88 — check mapping/units |
| (C) 0.13 = EBIT TTM 4.74b / Avg Total Assets 35.79b |
| (D) 2.89 = Book Value of Equity 31.05b / Total Liabilities 10.73b |
| Total Rating: 12.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.84
| 1. Piotroski 5.0pt |
| 2. FCF Yield 6.31% |
| 3. FCF Margin 9.63% |
| 4. Debt/Equity 0.25 |
| 5. Debt/Ebitda 0.63 |
| 6. ROIC - WACC (= 4.61)% |
| 7. RoE 14.71% |
| 8. Rev. Trend 32.19% |
| 9. EPS Trend -35.76% |
What is the price of DHI shares?
As of December 08, 2025, the stock is trading at USD 158.62 with a total of 1,732,804 shares traded.
Over the past week, the price has changed by +0.79%, over one month by +9.91%, over three months by -13.55% and over the past year by -0.28%.
Over the past week, the price has changed by +0.79%, over one month by +9.91%, over three months by -13.55% and over the past year by -0.28%.
Is DHI a buy, sell or hold?
DR Horton has received a consensus analysts rating of 3.62.
Therefor, it is recommend to hold DHI.
- Strong Buy: 6
- Buy: 3
- Hold: 10
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the DHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 163.6 | 3.1% |
| Analysts Target Price | 163.6 | 3.1% |
| ValueRay Target Price | 173.9 | 9.6% |
DHI Fundamental Data Overview December 05, 2025
Market Cap USD = 49.19b (49.19b USD * 1.0 USD.USD)
P/E Trailing = 14.261
P/E Forward = 13.8504
P/S = 1.4362
P/B = 1.9
P/EG = 1.2125
Beta = 1.386
Revenue TTM = 34.25b USD
EBIT TTM = 4.74b USD
EBITDA TTM = 4.84b USD
Long Term Debt = 5.97b USD (from longTermDebt, last quarter)
Short Term Debt = 5.97b USD (from shortTermDebt, last quarter)
Debt = 6.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.05b USD (from netDebt column, last quarter)
Enterprise Value = 52.24b USD (49.19b + Debt 6.03b - CCE 2.99b)
Interest Coverage Ratio = 156.4 (Ebit TTM 4.74b / Interest Expense TTM 30.3m)
FCF Yield = 6.31% (FCF TTM 3.30b / Enterprise Value 52.24b)
FCF Margin = 9.63% (FCF TTM 3.30b / Revenue TTM 34.25b)
Net Margin = 10.47% (Net Income TTM 3.59b / Revenue TTM 34.25b)
Gross Margin = 23.70% ((Revenue TTM 34.25b - Cost of Revenue TTM 26.13b) / Revenue TTM)
Gross Margin QoQ = 21.67% (prev 23.95%)
Tobins Q-Ratio = 1.47 (Enterprise Value 52.24b / Total Assets 35.47b)
Interest Expense / Debt = 0.50% (Interest Expense 30.3m / Debt 6.03b)
Taxrate = 23.90% (288.0m / 1.20b)
NOPAT = 3.61b (EBIT 4.74b * (1 - 23.90%))
Current Ratio = 17.39 (Total Current Assets 34.14b / Total Current Liabilities 1.96b)
Debt / Equity = 0.25 (Debt 6.03b / totalStockholderEquity, last quarter 24.19b)
Debt / EBITDA = 0.63 (Net Debt 3.05b / EBITDA 4.84b)
Debt / FCF = 0.92 (Net Debt 3.05b / FCF TTM 3.30b)
Total Stockholder Equity = 24.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.11% (Net Income 3.59b / Total Assets 35.47b)
RoE = 14.71% (Net Income TTM 3.59b / Total Stockholder Equity 24.38b)
RoCE = 15.62% (EBIT 4.74b / Capital Employed (Equity 24.38b + L.T.Debt 5.97b))
RoIC = 11.79% (NOPAT 3.61b / Invested Capital 30.59b)
WACC = 7.19% (E(49.19b)/V(55.22b) * Re(8.02%) + D(6.03b)/V(55.22b) * Rd(0.50%) * (1-Tc(0.24)))
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.88%
[DCF Debug] Terminal Value 78.95% ; FCFE base≈2.81b ; Y1≈2.94b ; Y5≈3.42b
Fair Price DCF = 205.4 (DCF Value 59.98b / Shares Outstanding 292.1m; 5y FCF grow 5.06% → 3.0% )
EPS Correlation: -35.76 | EPS CAGR: -1.11% | SUE: -0.85 | # QB: 0
Revenue Correlation: 32.19 | Revenue CAGR: 8.80% | SUE: 0.62 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.49 | Chg30d=-0.027 | Revisions Net=-8 | Analysts=13
EPS current Year (2026-09-30): EPS=11.44 | Chg30d=-0.008 | Revisions Net=-10 | Growth EPS=-1.1% | Growth Revenue=+0.4%
EPS next Year (2027-09-30): EPS=13.48 | Chg30d=+0.017 | Revisions Net=-5 | Growth EPS=+17.9% | Growth Revenue=+6.6%
P/E Trailing = 14.261
P/E Forward = 13.8504
P/S = 1.4362
P/B = 1.9
P/EG = 1.2125
Beta = 1.386
Revenue TTM = 34.25b USD
EBIT TTM = 4.74b USD
EBITDA TTM = 4.84b USD
Long Term Debt = 5.97b USD (from longTermDebt, last quarter)
Short Term Debt = 5.97b USD (from shortTermDebt, last quarter)
Debt = 6.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.05b USD (from netDebt column, last quarter)
Enterprise Value = 52.24b USD (49.19b + Debt 6.03b - CCE 2.99b)
Interest Coverage Ratio = 156.4 (Ebit TTM 4.74b / Interest Expense TTM 30.3m)
FCF Yield = 6.31% (FCF TTM 3.30b / Enterprise Value 52.24b)
FCF Margin = 9.63% (FCF TTM 3.30b / Revenue TTM 34.25b)
Net Margin = 10.47% (Net Income TTM 3.59b / Revenue TTM 34.25b)
Gross Margin = 23.70% ((Revenue TTM 34.25b - Cost of Revenue TTM 26.13b) / Revenue TTM)
Gross Margin QoQ = 21.67% (prev 23.95%)
Tobins Q-Ratio = 1.47 (Enterprise Value 52.24b / Total Assets 35.47b)
Interest Expense / Debt = 0.50% (Interest Expense 30.3m / Debt 6.03b)
Taxrate = 23.90% (288.0m / 1.20b)
NOPAT = 3.61b (EBIT 4.74b * (1 - 23.90%))
Current Ratio = 17.39 (Total Current Assets 34.14b / Total Current Liabilities 1.96b)
Debt / Equity = 0.25 (Debt 6.03b / totalStockholderEquity, last quarter 24.19b)
Debt / EBITDA = 0.63 (Net Debt 3.05b / EBITDA 4.84b)
Debt / FCF = 0.92 (Net Debt 3.05b / FCF TTM 3.30b)
Total Stockholder Equity = 24.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.11% (Net Income 3.59b / Total Assets 35.47b)
RoE = 14.71% (Net Income TTM 3.59b / Total Stockholder Equity 24.38b)
RoCE = 15.62% (EBIT 4.74b / Capital Employed (Equity 24.38b + L.T.Debt 5.97b))
RoIC = 11.79% (NOPAT 3.61b / Invested Capital 30.59b)
WACC = 7.19% (E(49.19b)/V(55.22b) * Re(8.02%) + D(6.03b)/V(55.22b) * Rd(0.50%) * (1-Tc(0.24)))
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.88%
[DCF Debug] Terminal Value 78.95% ; FCFE base≈2.81b ; Y1≈2.94b ; Y5≈3.42b
Fair Price DCF = 205.4 (DCF Value 59.98b / Shares Outstanding 292.1m; 5y FCF grow 5.06% → 3.0% )
EPS Correlation: -35.76 | EPS CAGR: -1.11% | SUE: -0.85 | # QB: 0
Revenue Correlation: 32.19 | Revenue CAGR: 8.80% | SUE: 0.62 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.49 | Chg30d=-0.027 | Revisions Net=-8 | Analysts=13
EPS current Year (2026-09-30): EPS=11.44 | Chg30d=-0.008 | Revisions Net=-10 | Growth EPS=-1.1% | Growth Revenue=+0.4%
EPS next Year (2027-09-30): EPS=13.48 | Chg30d=+0.017 | Revisions Net=-5 | Growth EPS=+17.9% | Growth Revenue=+6.6%
Additional Sources for DHI Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle